Want to see TSE:CL full AI Analyst Report?

Cresco Labs (CL) Stock Forecast & Price Target

205 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

CL Analyst Ratings

Strong Buy

3 Buy

0 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Cresco

Labs

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

CL Stock 12 Month Forecast

Average Price Target

C$2.54

▲(148.85% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Cresco Labs in the last 3 months. The average price target is C$2.54 with a high forecast of C$2.81 and a low forecast of C$2.30. The average price target represents a 148.85% change from the last price of C$1.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"C$0","1":"C$1","2":"C$2","3":"C$3","-1":"-C$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.8149587,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">C$2.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5383195666666665,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">C$2.54</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">C$2.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.1765352846153847,1.3130705692307694,1.4496058538461538,1.5861411384615385,1.7226764230769231,1.8592117076923076,1.9957469923076923,2.132282276923077,2.2688175615384614,2.4053528461538463,2.5418881307692307,2.678423415384615,{"y":2.8149587,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.1552553512820514,1.2705107025641025,1.3857660538461538,1.5010214051282051,1.6162767564102563,1.7315321076923076,1.846787458974359,1.9620428102564103,2.0772981615384616,2.1925535128205125,2.3078088641025643,2.423064215384615,{"y":2.5383195666666665,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.04,1.136923076923077,1.2338461538461538,1.3307692307692307,1.4276923076923076,1.5246153846153845,1.6215384615384614,1.7184615384615385,1.8153846153846152,1.9123076923076923,2.009230769230769,2.106153846153846,2.2030769230769227,{"y":2.3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.66,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.25,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.31,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.9,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetC$2.81

Average Price TargetC$2.54

Lowest Price TargetC$2.30

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Bill Kirk

Roth MKM

C$2.81

Buy

175.98%

Upside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cresco Labs (Other OTC: CRLBF)

Neal Gilmer

Haywood

C$2.3

Buy

125.49%

Upside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cresco Labs (Other OTC: CRLBF), Prime Medicine, Inc. (NASDAQ: PRME) and Steris (NYSE: STE)

Aaron Grey

Alliance Global Partners

C$3.25→C$2.5

Buy

145.10%

Upside

Reiterated

08/06/26

Cresco Labs price target lowered to C$2.50 from C$3.25 at Alliance GlobalCresco Labs price target lowered to C$2.50 from C$3.25 at Alliance Global

Luke Hannan

Canaccord Genuity

C$2.5→C$2.25

Buy

120.59%

Upside

Reiterated

03/06/26

Cresco Labs price target lowered to C$2.25 from C$2.50 at CanaccordCresco Labs price target lowered to C$2.25 from C$2.50 at Canaccord

Frederico Gomes

ATB Cormark Capital Markets

C$2.5→C$2.25

Buy

120.59%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI) and Cresco Labs (Other OTC: CRLBF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Bill Kirk

Roth MKM

C$2.81

Buy

175.98%

Upside

Reiterated

08/07/26

Analysts Offer Insights on Healthcare Companies: Alkermes (NASDAQ: ALKS), BioMarin Pharmaceutical (NASDAQ: BMRN) and Cresco Labs (Other OTC: CRLBF)

Neal Gilmer

Haywood

C$2.3

Buy

125.49%

Upside

Reiterated

08/06/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cresco Labs (Other OTC: CRLBF), Prime Medicine, Inc. (NASDAQ: PRME) and Steris (NYSE: STE)

Aaron Grey

Alliance Global Partners

C$3.25→C$2.5

Buy

145.10%

Upside

Reiterated

08/06/26

Cresco Labs price target lowered to C$2.50 from C$3.25 at Alliance GlobalCresco Labs price target lowered to C$2.50 from C$3.25 at Alliance Global

Luke Hannan

Canaccord Genuity

C$2.5→C$2.25

Buy

120.59%

Upside

Reiterated

03/06/26

Cresco Labs price target lowered to C$2.25 from C$2.50 at CanaccordCresco Labs price target lowered to C$2.25 from C$2.50 at Canaccord

Frederico Gomes

ATB Cormark Capital Markets

C$2.5→C$2.25

Buy

120.59%

Upside

Reiterated

03/06/26

Analysts Offer Insights on Healthcare Companies: OmniAb (NASDAQ: OABI) and Cresco Labs (Other OTC: CRLBF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

LFMDLifeMD

ORKAOruka Therapeutics

ACHVAchieve Life Sciences

PLSEPulse Biosciences

PMNProMIS Neurosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Cresco Labs

3 Months

Neal GilmerHaywood

Success Rate

6/18 ratings generated profit

Average Return

+4.92%

Copying Neal Gilmer's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of +4.92% per trade.

1 Year

Aaron GreyAlliance Global Partners

Success Rate

5/11 ratings generated profit

Average Return

-14.13%

Copying Aaron Grey's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -14.13% per trade.

2 Years

Neal GilmerHaywood

Success Rate

5/18 ratings generated profit

Average Return

-28.33%

Copying Neal Gilmer's trades and holding each position for 2 Years would result in 27.78% of your transactions generating a profit, with an average return of -28.33% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CL Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, CL has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CL average Analyst price target in the past 3 months is 2.54.

Each month's total comprises the sum of three months' worth of ratings.

CL Financial Forecast

CL Earnings Forecast

Next quarter’s earnings estimate for CL is -C$0.02 with a range of -C$0.06 to C$0.01. The previous quarter’s EPS was C$0.06. CL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year CL has Performed in-line its overall industry.

CL Sales Forecast

Next quarter’s sales forecast for CL is C$239.17M with a range of C$236.19M to C$241.15M. The previous quarter’s sales results were C$239.97M. CL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year CL has Performed in-line its overall industry.

CL Stock Forecast FAQ

What is TSE:CL’s average 12-month price target, according to analysts?

Based on analyst ratings, Cresco Labs’s 12-month average price target is 2.54.

What is TSE:CL’s upside potential, based on the analysts’ average price target?

Cresco Labs has 148.85% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is TSE:CL a Buy, Sell or Hold?

Cresco Labs has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.

What is Cresco Labs’s price target?

The average price target for Cresco Labs is 2.54. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is C$2.81 ,the lowest forecast is C$2.30. The average price target represents 148.85% Increase from the current price of C$1.02.

What do analysts say about Cresco Labs?

Cresco Labs’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of TSE:CL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Cresco Labs (CL) Stock Forecast & Price Target

CL Analyst Ratings

CL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Cresco Labs

CL Analyst Recommendation Trends

CL Financial Forecast

CL Earnings Forecast

CL Sales Forecast

CL Stock Forecast FAQ

Detailed List of Analyst Forecasts